首页> 美国卫生研究院文献>BMC Complementary and Alternative Medicine >2-Ethoxystypandrone a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells
【2h】

2-Ethoxystypandrone a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells

机译:虎杖中的一种新型小分子STAT3信号抑制剂2-乙氧基stydandradrone抑制细胞生长并诱导HCC细胞和HCC癌症干细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundSignal transducer and activator of transcription 3 (STAT3) is an oncogene constitutively activated in hepatocellular carcinoma (HCC) cells and HCC cancer stem cells (CSCs). Constitutively activated STAT3 plays a pivotal role in holding cancer stemness of HCC CSCs, which are essential for hepatoma initiation, relapse, metastasis and drug resistance. Therefore, STAT3 has been validated as a novel anti-cancer drug target and the strategies targeting HCC CSCs may bring new hopes to HCC therapy. This study aimed to isolate and identify small-molecule STAT3 signaling inhibitors targeting CSCs from the ethyl acetate (EtOAc) extract of the roots of Polygonum cuspidatum and to evaluate their in vitro anti-cancer activities.
机译:背景信号转导和转录激活因子3(STAT3)是在肝细胞癌(HCC)细胞和HCC癌症干细胞(CSC)中组成性激活的癌基因。组成性激活的STAT3在保持HCC CSC的癌干性中起着关键作用,这对于肝癌的发生,复发,转移和耐药性至关重要。因此,STAT3已被证实是一种新型的抗癌药物,靶向HCC CSCs的策略可能为HCC治疗带来新的希望。这项研究旨在从虎杖根的乙酸乙酯(EtOAc)提取物中分离和鉴定靶向CSC的小分子STAT3信号抑制剂,并评估其体外抗癌活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号